Found Tirzepatide Pricing: Is Found Worth It?
Detailed analysis of Found's tirzepatide costs in 2026, what is included, what each plan length costs, and whether Found provides enough value compared to more affordable GLP-1 providers.
More on GLP-1 Provider Comparisons
Found's Tirzepatide Program: What You Get and What You Pay
Found introduced tirzepatide to its medication options as demand for the dual GIP/GLP-1 receptor agonist surged following Eli Lilly's Zepbound approval. Tirzepatide has captured enormous patient interest because clinical trial data suggests it may produce greater weight loss than semaglutide alone, up to 22.5% body weight reduction in the SURMOUNT trials versus approximately 15% in the semaglutide STEP trials. Found, recognizing this demand, now offers compounded tirzepatide as part of its weight loss platform.
However, tirzepatide does not come cheap on Found's platform. As of 28 September 2026, Found charges $239 to $359 per 28-day cycle for compounded tirzepatide on cash pay, $60 to $70 more per cycle than its semaglutide plans. That premium reflects the genuinely higher cost of compounding tirzepatide: the molecule is more complex, raw materials are more expensive, and the compounding process requires more specialized handling.
Found's tirzepatide program includes the same core services as its semaglutide program: telehealth provider consultations, access to the Found app with behavioral coaching tools, personalized treatment planning, and the compounded medication itself. The key question for patients is whether Found's app ecosystem and behavioral layer provide enough additional value to justify paying significantly more than a provider like Trimi, which delivers the same medication with equivalent clinical supervision at a substantially lower monthly cost.
Tirzepatide vs. Semaglutide Pricing
Tirzepatide is more expensive than semaglutide at every provider. This reflects genuine cost differences in compounding. However, the price gap varies widely between providers, compare the tirzepatide premium specifically, not just headline prices.
Detailed Cost Comparison: Found Tirzepatide vs. Alternatives
Understanding where Found's tirzepatide pricing sits relative to the broader market is essential for making an informed decision. The telehealth GLP-1 landscape in 2026 includes providers at every price point, from premium concierge programs to streamlined, cost-efficient platforms. Found's positioning in this landscape tells you what you are paying for, and what you might save by choosing differently.
| Feature | Found | Trimi | Calibrate | Sequence |
|---|---|---|---|---|
| Tirzepatide monthly cost | $239–$359 per 28 days (cash pay) | $125 annual plan, $235 monthly | $300–$450+ | $249–$399 |
| Medication included | Yes | Yes | Varies | Yes |
| Provider visits | Included | Included | Included | Included |
| Behavioral app/tools | Yes | Basic | Yes (intensive) | Yes |
| Flat pricing at all doses | Yes | Yes | No | No |
| Cancellation fees | Varies | None | Yes | Varies |
| 12-month estimated cost | From $2,868 (12-month plan) | $1,500 (annual plan) | $3,600–$5,400+ | $2,988–$4,788 |
As the table illustrates, Found sits in the middle of the tirzepatide pricing spectrum. It is less expensive than premium providers like Calibrate and Sequence, but considerably more expensive than Trimi. The annual cost difference between Found and Trimi for tirzepatide is at least $1,368 on comparable 12-month plans, a meaningful amount for patients budgeting for a treatment course that typically lasts twelve to eighteen months.
Does Found's Price Change as Your Dose Goes Up?
One of the most important pricing dynamics to understand with Found's tirzepatide program is how costs change during dose escalation. Tirzepatide treatment follows a standard titration protocol: patients typically start at 2.5 mg weekly and gradually increase to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and potentially 15 mg over several months. This titration is clinically necessary to manage side effects and allow the body to adjust to the medication.
No. Found states that its compounded tirzepatide costs the same at every dose, so moving from 2.5 mg to a 10 mg or 15 mg maintenance dose does not change the plan price. The price change to plan for is on the month-to-month plan: the first cycle is $219 on cash pay, and every cycle after that is $359. Longer plans lower the price per cycle to $309 (3 months), $289 (6 months), or $239 (12 months).
Trimi also charges one price at every tirzepatide dose, $125 per month on the annual plan or $235 month to month, so your cost at 2.5 mg is the same as at 15 mg with either provider. The difference between the two is the price level, not how it behaves as you titrate.
When evaluating any provider's tirzepatide pricing, still ask: what will I pay at the dose my provider expects me to maintain, and what happens after any introductory month? Understanding the tirzepatide dosing schedule and side effects can help you anticipate what dose range you are likely to end up at and plan your budget accordingly.
Who Should Consider Found for Tirzepatide?
Despite its higher pricing, Found's tirzepatide program may be appropriate for certain patient profiles. Understanding who genuinely benefits from Found's approach versus who is overpaying for features they do not need is critical to making a cost-effective decision.
Patients who strongly value app-based behavioral coaching and structured programs may find Found's technology worth the premium
Patients who have tried medication-only approaches and felt they needed more accountability tools may benefit from Found's ecosystem
Budget-conscious patients primarily seeking supervised tirzepatide access should compare Found against lower-cost providers like Trimi
Patients who want flat, predictable pricing regardless of dose should consider providers with dose-independent pricing models
Ultimately, tirzepatide's clinical efficacy is a function of the medication and appropriate medical supervision, not the platform delivering it. A patient receiving tirzepatide through Trimi at a lower price is receiving the same pharmacological intervention as a patient on Found's more expensive platform. The difference is in the supplementary services, and whether those services are worth the hundreds or thousands of dollars in additional annual cost is a deeply personal calculation.
If you are currently on Found's tirzepatide program and feeling the financial strain, switching to a more affordable provider is straightforward. Our guide on switching from Found to Trimi covers the process, including how to ensure continuity of care and avoid gaps in your medication supply. You can also review our comprehensive Found Weight Loss review for a broader assessment of the platform's strengths and weaknesses.
The Bottom Line on Found Tirzepatide Pricing
Found offers a legitimate, medically supervised tirzepatide program with genuine strengths in its behavioral and technology layers. Its cash-pay pricing, $239 to $359 per 28-day cycle, is lower than premium providers but significantly higher than streamlined alternatives like Trimi. Its price does not rise with dose, but the month-to-month plan's first cycle is discounted, so budget from the $359 ongoing rate.
For patients who place high value on app-based coaching, behavioral tools, and a technology-integrated weight loss experience, Found's tirzepatide program may justify its premium. For patients whose primary need is safe, supervised access to effective tirzepatide at the lowest sustainable cost, the market now offers alternatives that deliver equivalent clinical outcomes at substantially lower price points. The choice depends on your budget, your preferences, and how much value you assign to the non-medication components of Found's platform.
Frequently Asked Questions
How much does Found charge for tirzepatide?
Found charges $239 per 28-day cycle for compounded tirzepatide on a 12-month cash-pay plan, $289 on 6 months, $309 on 3 months, or $219 for the first month and then $359 month to month, with the medication included and the same price at every dose. Insurance plans cost $179 to $289 per cycle, plus a copay for each required video visit, which Found says is typically around $30. Tirzepatide is typically priced higher than semaglutide across telehealth platforms because the compounding process is more complex and raw materials cost more. By comparison, Trimi charges $125 per month for compounded tirzepatide on the annual plan (a 12-month commitment) or $235 month to month, all-inclusive.
Is Found tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved finished drug made by Eli Lilly. Found's tirzepatide is compounded, meaning it is prepared by an state-licensed compounding pharmacy against an individual prescription and is not FDA-approved as a drug. It is legally available under FDA compounding regulations during the current shortage period. Compounded formulations have not undergone the clinical trials that brand-name products have.
Does tirzepatide work better than semaglutide for weight loss?
Clinical trial data suggests tirzepatide may produce greater average weight loss than semaglutide. The SURMOUNT-1 trial showed tirzepatide produced up to 22.5% body weight reduction at the highest dose, compared to approximately 15% with semaglutide in the STEP trials. However, individual results vary significantly, and some patients respond better to one medication than the other. Both are highly effective GLP-1 receptor agonists for weight management. Your prescribing provider can help determine which medication is most appropriate for your specific clinical profile.
Why is tirzepatide more expensive than semaglutide at Found?
Tirzepatide is generally more expensive than semaglutide across all telehealth providers, not just Found. The reasons include more complex compounding processes, higher raw material costs, and the dual GIP/GLP-1 mechanism that makes tirzepatide a more advanced molecule. Found passes these higher production costs to patients through higher monthly subscription prices. Some providers absorb more of this cost difference than others, Trimi, for instance, keeps the tirzepatide-to-semaglutide price gap smaller than many competitors.
Can I switch from semaglutide to tirzepatide on Found?
Yes, Found does allow patients to switch between semaglutide and tirzepatide, subject to medical approval from their Found provider. The switch typically involves a telehealth consultation to discuss the clinical rationale, a new dosing protocol (since the medications are not interchangeable at a dose-for-dose level), and a plan price change. On Found's cash-pay plans, compounded tirzepatide costs $60 to $70 more per 28-day cycle than semaglutide depending on plan length ($239 versus $169 on a 12-month plan), regardless of dose.
Is Found's tirzepatide program worth the premium over semaglutide?
Whether tirzepatide is worth the premium over semaglutide depends on your individual clinical response and budget. If you have tried semaglutide and found it insufficiently effective or are experiencing limiting side effects, tirzepatide's different mechanism of action may produce better results. However, if cost is a primary concern, starting with semaglutide at a lower price point and switching only if needed is a financially prudent approach. Trimi offers both semaglutide and tirzepatide at lower prices than Found, giving patients flexibility to try either medication without overpaying.
How does Found's tirzepatide pricing compare to Trimi?
Found charges $239 to $359 per 28-day cycle for compounded tirzepatide on cash pay, and Trimi charges $125 per month on its annual plan (a 12-month commitment) or $235 month to month. Both include provider consultations and compounded medication, and neither changes price with dose. On the 12-month plans, Trimi costs at least $1,368 less over a year ($114 a month times 12), with equivalent clinical oversight.
Sources & References
- Found compounded tirzepatide plan page and plans and pricing, accessed 28 September 2026.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." NEJM, 2022;387:205-216 (SURMOUNT-1).
- Zepbound prescribing information from the FDA.
- STEP 1 trial: semaglutide in adults with overweight or obesity (PubMed).
- FDA guidance on compounding and the FDA.
- Frias JP, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." NEJM, 2021;385:503-515.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Pricing information is based on publicly available data and may vary. Trimi is a competing provider; this comparison is presented fairly but readers should verify current pricing directly with each provider.